TREATMENT OF NON-SECRETING PITUITARY ADENOMAS WITH CHIMERIC MOLECULES

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该项目已被安排在MR 7 T日历上，从7月7日开始，每周一至9月22日（共12次扫描），每只动物每月一次，持续4-5个月;小鼠在6-8个月大时发生垂体瘤。 目标1：比较嵌合分子（生长抑素和多巴胺的嵌合体）与纯生长抑素和多巴胺药物在阻止垂体腺瘤生长方面的有效性。 目标二：确定携带垂体腺瘤并接受嵌合分子治疗的小鼠与仅接受载体治疗的小鼠的存活率（后一组小鼠将在10-11月龄时死亡）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project has been scheduled on the MR 7T calendar starting on July 7, with reservations for every Monday through Sept 22 ( a total of 12 scanning sessions), once/month per animal for 4-5 months; mice develop pituitary tumors by 6-8 months of age. Aim 1: Compare the proven effectiveness in halting pituitary adenoma growth of a chimeric molecule (chimera of somatostatin and dopomine) to that of a pure somatostatin and dopamine drug. Aim 2: Determine the survival of mice carrying pituitary adenomas and being treated with the chimeric molecule versus just vehicle (the latter group will die by 10-11 months of age).